Short answer · Medically reviewed summary · Last updated: 2026-05-08
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an ultra-rare, severe genetic disorder with an estimated prevalence of less than 1 in 1,000,000 individuals worldwide. Due to its extreme rarity and high mortality rate, exact incidence and prevalence figures remain difficult to calculate, and the condition is frequently underdiagnosed or misdiagnosed as other forms of spinal muscular atrophy. Is the prevalence of SMARD1 well-defined? Because Spinal muscular atrophy with respiratory distress type 1 is an ultra-rare condition, global epidemiological data is limited.
What is the prevalence of Spinal muscular atrophy with respiratory distress type 1?
Prevalence of Spinal muscular atrophy with respiratory distress type 1: how many people are affected worldwide, differences by sex and region, with sources.
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an ultra-rare, severe genetic disorder with an estimated prevalence of less than 1 in 1,000,000 individuals worldwide. Due to its extreme rarity and high mortality rate, exact incidence and prevalence figures remain difficult to calculate, and the condition is frequently underdiagnosed or misdiagnosed as other forms of spinal muscular atrophy.
Is the prevalence of SMARD1 well-defined?
Because Spinal muscular atrophy with respiratory distress type 1 is an ultra-rare condition, global epidemiological data is limited. According to Orphanet, the prevalence is estimated to be less than 1 in 1,000,000. While these numbers provide a baseline, the actual number of people living with Spinal muscular atrophy with respiratory distress type 1 may be higher, as cases are often misidentified in clinical settings due to the overlap of symptoms with more common neuromuscular disorders.
What is the typical age of onset and distribution?
Spinal muscular atrophy with respiratory distress type 1 is primarily a pediatric-onset disorder. Symptoms typically appear within the first six months of life, often manifesting as respiratory failure and distal muscle weakness. There is no known predilection for sex or ethnicity, meaning Spinal muscular atrophy with respiratory distress type 1 affects males and females equally across all populations.
Why is accurate data collection for SMARD1 challenging?
Several factors complicate our understanding of Spinal muscular atrophy with respiratory distress type 1 statistics:
- Diagnostic Delay: The clinical presentation of Spinal muscular atrophy with respiratory distress type 1 mimics other infant-onset motor neuron diseases.
- Genetic Complexity: Mutations in the IGHMBP2 gene are required for a definitive diagnosis, and genetic testing is not universally accessible.
- Disease Severity: The high mortality rate in early infancy often leads to under-reporting in long-term prevalence registries.
Our DiseaseMaps.org community currently includes 47 people living with Spinal muscular atrophy with respiratory distress type 1, providing a vital, real-world perspective that complements clinical databases by capturing the lived experience of those navigating this rare diagnosis.
Next steps
- Consult with a pediatric neurologist or a clinical geneticist to confirm a molecular diagnosis via IGHMBP2 gene sequencing.
- Connect with the DiseaseMaps.org community to share experiences with other families managing this condition.
- Reach out to organizations like the Gwendolyn Strong Foundation or the SMA Foundation for specialized resources.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician with any questions regarding a medical condition.
References
- Orphanet: Rare disease database (ORPHA:3247).
- NIH Genetic and Rare Diseases Information Center (GARD): Spinal muscular atrophy with respiratory distress type 1.
- OMIM (Online Mendelian Inheritance in Man): Entry #604320.
